Company’s 36-month beta value is -0.90.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CADL is 36.70M, and currently, short sellers hold a 17.06% ratio of that floaft. The average trading volume of CADL on July 09, 2025 was 924.14K shares.
CADL) stock’s latest price update
Candel Therapeutics Inc (NASDAQ: CADL)’s stock price has gone rise by 14.69% in comparison to its previous close of $5.24, however, the company has experienced a 23.92% increase in its stock price over the last five trading days. proactiveinvestors.com reported 2025-07-09 that Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective with the opening of the US markets on June 30.
CADL’s Market Performance
CADL’s stock has risen by 23.92% in the past week, with a monthly drop of -0.50% and a quarterly rise of 24.17%. The volatility ratio for the week is 4.90% while the volatility levels for the last 30 days are 6.32% for Candel Therapeutics Inc The simple moving average for the past 20 days is 17.72% for CADL’s stock, with a -5.80% simple moving average for the past 200 days.
Analysts’ Opinion of CADL
Many brokerage firms have already submitted their reports for CADL stocks, with H.C. Wainwright repeating the rating for CADL by listing it as a “Buy.” The predicted price for CADL in the upcoming period, according to H.C. Wainwright is $23 based on the research report published on June 30, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see CADL reach a price target of $25. The rating they have provided for CADL stocks is “Buy” according to the report published on February 20th, 2025.
Canaccord Genuity gave a rating of “Buy” to CADL, setting the target price at $20 in the report published on February 19th of the current year.
CADL Trading at 14.67% from the 50-Day Moving Average
After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.84% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CADL starting from Nichols William Garrett, who sale 781 shares at the price of $5.04 back on Jun 30 ’25. After this action, Nichols William Garrett now owns 52,493 shares of Candel Therapeutics Inc, valued at $3,936 using the latest closing price.
Stock Fundamentals for CADL
The total capital return value is set at -0.44. Equity return is now at value -98.14, with -62.27 for asset returns.
Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.72. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -29.52.
Currently, EBITDA for the company is -52.1 million with net debt to EBITDA at 1.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.64.
Conclusion
In a nutshell, Candel Therapeutics Inc (CADL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
